BRINC Raises $125 Million to Expand Public Safety Drone Platform and U.S. Manufacturing

BRINC, a developer of public safety drone technology, has raised $125 million in a financing round led by Motorola Solutions, with participation from Index Ventures and Figma CEO Dylan Field, to expand manufacturing and accelerate deployment of emergency response drones across the United States.

The latest financing brings the company’s total funding to more than $250 million and will support its goal of equipping 80,000 police and fire stations nationwide with 911 response drones.

The capital will fund expanded U.S. manufacturing, new product development, and go-to-market growth. BRINC said it will move into a new manufacturing facility by year-end that is three times larger than its current factory, significantly increasing production capacity.

“Every second matters in an emergency,” said Blake Resnick, Founder and CEO of BRINC. “Our 911 response drones put eyes on scene before first responders arrive, giving everyone the situational awareness they need to act decisively and keep people safe.”

The company reported strong commercial momentum, with revenue more than tripling in 2025 while monthly production capacity increased fivefold. BRINC also said it has signed nearly four times as many 911 response drone contracts this year compared with the same period in 2025, including deployments with the Los Angeles Fire Department, St. Louis Police Department, and hundreds of other public safety agencies.

BRINC’s product lineup includes the Lemur 2 indoor drone, the Responder drone designed for extended on-scene operations, and the Guardian, a 911 response platform intended to provide rapid aerial situational awareness. The company’s drones integrate with Motorola Solutions’ public safety technologies and interoperate with other emergency response platforms.

Founded to develop technology for emergency responders, BRINC manufactures its products in the United States through a vertically integrated supply chain. Its systems are now used by more than 900 public safety agencies, including over 20% of U.S. SWAT teams, according to the company.

Source link

Fulflex Acquires 300,000-Square-Foot Texas Medical Manufacturing Facility to Expand U.S. Healthcare Platform

Fulflex Acquires 300,000-Square-Foot, Fully Automated Medical Products Manufacturing Facility In Texas

Fulflex has completed the acquisition of a 300,000-square-foot medical products manufacturing facility in Jacksonville, Texas, significantly expanding its North American production capacity and reinforcing its strategy to build a larger global healthcare manufacturing platform.

Located on a 30-acre campus, the facility becomes one of Fulflex’s largest and most advanced manufacturing sites worldwide. The acquisition also brings more than 250 employees into the company, strengthening its manufacturing workforce while establishing a larger operational presence in East Texas.

The Jacksonville facility produces a broad range of medical products used by healthcare providers and patients globally. Its manufacturing capabilities include plastics injection molding, blow molding, thermoforming, extrusion, automated assembly and other advanced production technologies, enabling Fulflex to increase output while supporting customers with scalable, high-quality manufacturing solutions.

“This is an exciting day for Fulflex and for the Jacksonville community,” said Diya Garware Ibanez, Chairperson of Fulflex. “We are delighted to officially welcome the Jacksonville team into the Fulflex family. This acquisition reflects our confidence in the exceptional people, the advanced manufacturing capabilities of this facility, and the long-term future of healthcare manufacturing in East Texas. We are committed to investing in this facility, creating new opportunities for our employees, supporting our customers with world-class manufacturing, and contributing positively to the Jacksonville community for many years to come.”

The acquisition expands Fulflex’s manufacturing footprint across North America while increasing capacity in polymer processing, medical device manufacturing and automated production. The additional facility also enhances supply chain resilience by providing greater geographic diversification and production flexibility for customers operating in global healthcare markets.

The investment aligns with Fulflex’s long-term strategy of expanding through advanced manufacturing assets that strengthen operational scale and support growing demand for medical products. The company said it plans to build on the Jacksonville facility’s existing capabilities through continued investments in manufacturing technology, quality systems, operational excellence and workforce development.

“Every acquisition begins and ends with people,” Garware Ibanez said. “The dedication, experience, and commitment of the Jacksonville employees are the foundation of this facility’s success. We are honored that so many talented people have chosen to continue this journey with us, and we look forward to building an organization where our employees can grow, our customers can succeed, and our community can thrive.”

The transition was formally marked with a community event attended by employees, customers, local officials and business leaders, underscoring the company’s commitment to maintaining the facility’s operations while investing in its long-term growth.

Following the acquisition, Fulflex operates 14 locations worldwide, including four manufacturing facilities in the United States, one manufacturing facility in the Dominican Republic, two manufacturing facilities in India, and seven sales offices and distribution centers across eight countries. The company’s global network serves customers in more than 85 countries, providing medical products and engineered polymer solutions for applications spanning medical devices, patient care, rehabilitation and personal protective equipment.

By expanding its U.S. manufacturing base with one of its largest production facilities, Fulflex is positioning itself to support increasing demand from healthcare customers while strengthening its role as a global contract manufacturing partner with enhanced capacity, operational flexibility and regional supply chain capabilities.

Source link

Bluejay Diagnostics Partners with Argonaut Manufacturing Services to Enhance U.S. Manufacturing for Symphony™ Platform

ACTON, Mass. and CARLSBAD, Calif., June 02, 2026 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”) (NASDAQ: BJDX), a medical diagnostics company focused on near-patient testing for critical care, today announced a strategic partnership with Argonaut Manufacturing Services (“Argonaut”) to support the advancement of Bluejay’s Symphony™ platform.

This partnership is designed to support Bluejay’s broader efforts to establish scalable U.S.-based manufacturing capabilities aligned with its ongoing clinical development programs and future commercialization objectives. In addition, the partnership is intended to strengthen Bluejay’s future commercial infrastructure by supporting broader product distribution across the United States, enhancing supply chain resilience, and reducing potential risks associated with international sourcing and import tariffs. The collaboration is also intended to mitigate risks associated with Bluejay’s current reliance on overseas manufacturing by establishing domestic manufacturing capabilities that can provide greater operational control, business continuity, and supply chain security. By leveraging U.S.-based manufacturing and distribution capabilities, Bluejay aims to improve operational flexibility, support future market demand, and further enhance its ability to commercialize innovative near-patient diagnostic solutions for critical care settings.

“We are pleased to partner with Argonaut as we continue to advance the Symphony™ platform,” said Neil Dey, President and Chief Executive Officer of Bluejay Diagnostics. “This collaboration reflects our commitment to building a scalable and quality-focused operational foundation as we progress toward key commercial milestones.”

“Argonaut is committed to partnering with innovative companies to support the advancement of differentiated diagnostic technologies,” said Rick Hancock, Chief Executive Officer of Argonaut Manufacturing Services. “We value this collaboration with Bluejay Diagnostics and look forward to supporting their efforts as they continue to develop solutions aimed at improving clinical decision-making in critical care settings.”

Note: Investigational device. Limited by United States law to investigational use.

About the SYMON Clinical Study Program:

The SYMON Clinical Study Program includes SYMON-I (clinicaltrials.gov ID NCT06181604), SYMON-II (NCT06654895), and SYMON-III (NCT07425587). SYMON-I is a pilot study to determine IL-6 levels associated with various endpoints, including, but not limited to 28-day all-cause mortality and in-hospital mortality. The SYMON-II study is the pivotal study to validate the outcomes of the SYMON-I study, which the Company plans to use to support a 510(k) application to the FDA. The SYMON-III study is a pilot study to determine IL-6 levels associated with patients presenting with increasing severity of infection in the emergency department and risk of developing sepsis.

About Bluejay Diagnostics:

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ’sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.

About Argonaut Manufacturing Services:

Argonaut Manufacturing Services

is a contract manufacturing organization focused on supporting life sciences and diagnostics companies with high-quality manufacturing solutions. Founded by former executives from companies such as Thermo Fisher Scientific, Affymetrix, and Allergan, Argonaut was built to provide a better, customer-focused approach to contract manufacturing.

The company’s mission is centered on improving the human condition by helping partners bring innovative healthcare products to market efficiently and reliably. Drawing from decades of industry experience, Argonaut emphasizes quality, operational excellence, and strong customer collaboration to help clients achieve their commercial and development goals in the health and life sciences industries.

Forward-Looking Statements:

This press release contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest,” “will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions and those discussed under item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in Part II, Item 1A, “Risk Factors” in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company’s expectations of results or any future change in events, except as required by law.

Investor Contact:


Neil Dey

Bluejay Diagnostics, Inc.


[email protected]

Website: www.bluejaydx.com

Source link

FH Capital to Acquire 75.1 Percent Stake in JinkoSolar US Manufacturing Unit, Expand Solar and BESS Platform – Asia Pacific

FH Capital will acquire 75.1 percent of JinkoSolar’s US manufacturing subsidiary, expand 2 GW solar module capacity, and launch domestic BESS production to strengthen America’s clean energy manufacturing and supply chain.

May 13, 2026. By EI News Network

FH Capital has entered into an agreement to acquire a 75.1 percent majority stake in JinkoSolar’s US manufacturing subsidiary, creating a domestic solar and Battery Energy Storage Systems (BESS) platform anchored by a 2 GW solar module manufacturing facility in the United States. JinkoSolar will retain a 24.9 percent minority stake in the venture.

Following the transaction, FH Capital plans to inject additional expansion capital to at least double the facility’s current solar module production capacity while also launching domestic BESS manufacturing operations. The move is aimed at strengthening US-based clean energy manufacturing amid rising demand for locally sourced solar and storage products and evolving US energy policies.

FH Capital is led by Sanjeev Chaurasia, a renewable energy investment banker with more than two decades of experience. Chaurasia previously served as Managing Director at Credit Suisse, where he co-founded the firm’s renewable energy practice and led JinkoSolar’s 2010 NYSE IPO.

According to Chaurasia, the transaction combines JinkoSolar’s established US manufacturing presence, technology portfolio, and customer network with FH Capital’s investment and operational capabilities to support growing domestic solar and storage demand.

Nigel Cockroft, US General Manager of JinkoSolar, said that the partnership provides strategic direction and ownership support to expand manufacturing capacity and serve increasing demand for US-sourced renewable energy products.

The transaction remains subject to customary regulatory approvals and closing conditions. Financial details of the deal were not disclosed.

Source link

Nexans Acquires Republic Wire To Establish U.S. Manufacturing Platform In Low-Voltage Cable Market

Nexans, a Paris-based global electrification company, has signed an agreement to acquire 100% of Republic Wire, a family-owned American manufacturer of low-voltage copper and aluminum wire products headquartered in Cincinnati, Ohio. The deal, valued at approximately 680 million euros with a potential earn-out of up to 43 million euros, establishes Nexans’ first significant manufacturing and distribution platform in the United States and complements its recent acquisition of Electro Cables in Canada.

Founded in 1982, Republic Wire serves electrical wholesale distributors, utilities, and municipalities across the United States and Canada. The company operates a 32,500-square-meter manufacturing facility and a newly completed 30,000-square-meter warehouse and distribution center, employing more than 200 people. A recently completed expansion program is expected to be fully online by the end of 2026, increasing production capacity by approximately 30%. Republic Wire generated approximately 520 million euros in revenue over the twelve months through February 2026.

The U.S. low-voltage cable segment is estimated at approximately 12 billion euros and is driven by sustained demand across residential, commercial, and data center construction. Nexans projects approximately 23 million euros in run-rate synergies over three years, driven by commercial cross-selling, manufacturing technology deployment, and purchasing scale.

The transaction is expected to be immediately earnings-per-share accretive before synergies and is anticipated to close in the early third quarter of 2026, subject to regulatory approval. Republic Wire’s current management team, led by Ron and Jeremy Rosenbeck, will remain in place.

KEY QUOTES:

“The acquisition of Republic Wire marks a transformative moment in Nexans’ journey to become a reference pure player in electrification. The United States represents the single largest growth opportunity in low- and medium-voltage cable. Republic Wire gives us the expanded platform, the customer relationships and the operational credibility we need to compete in this highly dynamic market.”

Julien Hueber, Chief Executive Officer, Nexans

“Republic Wire has always been more than a business to our family — it is a legacy built on hard work, loyalty, and a deep responsibility to our customers and the people who chose to build their careers here. In Nexans, I found a partner who shares those values, not just a buyer.”

Ron Rosenbeck, CEO, Republic Wire

“The acquisition of Republic Wire represents an important strategic milestone, meaningfully strengthening our position in the North American market. As a highly respected brand with a proven track record of exceptional quality and customer centricity, Republic Wire brings deep market relationships and an extensive commercial network.”

Tim King, Managing Director North America, Nexans

Source link

Telix Advances Radiopharma Platform With Key Trials And US Manufacturing Shift

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.

• Telix Pharmaceuticals (ASX:TLX) has resubmitted its NDA for TLX101-Px, a PET imaging agent for brain cancer.

• The company reported that Part 1 of the global Phase 3 ProstACT study for TLX591-Tx in prostate cancer met primary safety and tolerability objectives.

• Telix expanded its U.S. manufacturing footprint with new cyclotron installations to support in-house radioisotope production and supply resilience.

At a share price of A$12.75, Telix Pharmaceuticals (ASX:TLX) sits against a mixed recent track record, with the stock up 12.9% over the past week and 43.6% over the past month, but showing a 54.4% decline over the past year. Over a longer period, the share price return sits at 87.2% over three years and 183.3% over five years. This provides context to the current interest around the company’s pipeline and manufacturing updates.

For investors watching Telix, the NDA resubmission for TLX101-Px, the Phase 3 safety readout for TLX591-Tx and the new U.S. cyclotron capacity are central elements of the current story. The way these clinical and operational milestones progress, and whether they lead to regulatory outcomes and commercial activity, is likely to influence sentiment on ASX:TLX.

Stay updated on the most important news stories for Telix Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Telix Pharmaceuticals.

ASX:TLX Earnings & Revenue Growth as at Mar 2026

3 things going right for Telix Pharmaceuticals that this headline doesn’t cover.

The NDA resubmission for TLX101-Px, the positive Part 1 readout from the ProstACT Phase 3 trial for TLX591-Tx, and the U.S. cyclotron rollout all point to Telix working on three parts of its model at once: diagnostics, therapeutics and infrastructure. TLX101-Px targets recurrent or progressive glioma, an area where the FDA currently has no approved targeted amino acid PET agent, so regulatory progress here would speak directly to Telix’s neuro-oncology focus and its companion diagnostic strategy alongside TLX101-Tx. On the prostate cancer side, acceptable safety and tolerability for TLX591-Tx in combination with standard therapies gives Telix more footing in a space where companies such as Novartis and Bayer are active with radioligand and oncology treatments. The cyclotron agreement in the U.S. moves Telix further into vertically integrated production, which can reduce dependence on external isotope suppliers compared with peers that lean more on contract manufacturers. For investors, the thread tying these updates together is execution risk: more assets and infrastructure can deepen the opportunity, but they also raise the bar on Telix’s ability to manage capital, regulatory interactions and complex supply chains over time.

• The NDA resubmission for TLX101-Px and progress in ProstACT Global align with the narrative of building a multiproduct, multi-region radiopharmaceutical platform across urologic and neuro-oncology indications.

• The extra data and statistical work needed for TLX101-Px, and the ongoing regulatory interactions for TLX591-Tx, highlight that clinical and regulatory pathways can be slower or more resource intensive than simple catalyst timelines might imply.

• The cyclotron rollout into RLS and TMS sites was anticipated in the narrative, but contract specific details such as the IBA agreement and ARTMS technology may not be fully captured in earlier assumptions about manufacturing integration and supply reliability.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Telix Pharmaceuticals to help decide what it’s worth to you.

• ⚠️ Heavier investment into clinical programs like ProstACT Global and into cyclotron infrastructure could keep reported earnings and margins under pressure if revenue does not keep pace.

• ⚠️ Regulatory processes for TLX101-Px and TLX591-Tx, together with existing regulatory scrutiny around prostate cancer disclosures, add uncertainty around timing and ultimate outcomes.

• 🎁 Progress across both diagnostic and therapeutic candidates, along with manufacturing integration, supports the idea of Telix evolving into a broader radiopharmaceutical platform rather than a single product story.

• 🎁 U.S. cyclotron capacity and in-house radioisotope production can improve supply chain resilience and may support more consistent availability of products versus competitors that rely mainly on third party isotope suppliers.

Investors should watch for the FDA’s response to the TLX101-Px NDA resubmission, including any further data requests, and updates on the transition of ProstACT Global into its larger Part 2 expansion and U.S. IND amendment. Progress on installing and qualifying the new U.S. cyclotrons, and how quickly they begin supplying Telix products at scale, will be key to understanding execution on the vertical integration plan. It is also worth tracking how Telix positions its prostate and brain cancer offerings in relation to radiopharma peers, and whether management provides clearer guidance on capital spend, margins and timelines as these programs and assets move through their next stages.

To ensure you’re always in the loop on how the latest news impacts the investment narrative for Telix Pharmaceuticals, head to the community page for Telix Pharmaceuticals to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include TLX.AX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Source link

Morph Systems, a defense industry and U.S. manufacturing data integration platform developer, announ..

Defense & U.S. Manufacturing Data Platform
Palantir Foundry Technology Utilization

사진 확대 A case of Morph Systems’ ontology construction that can identify relationships between unstructured data [Morph Systems]

Morph Systems, a defense industry and U.S. manufacturing data integration platform developer, announced on the 20th that it has attracted pre-seed investment from Mashup Ventures and 500 Global.

Morph Systems is an enterprise AI company that designs supply chain data and workflow for defense and U.S. manufacturing companies that are pushing for utilization advancement after the introduction of Palantir. Establish an ontology model that systematically defines data relationships according to the customer’s work context, and design data flows so that ERP (company resource management), logistics, settlement, and operation data can lead to actual decision-making and execution.

In addition, for organizations in the early stages of Palantir introduction, data and work structure design is also being carried out considering future expansion. Customers can have a data processing structure and a high-performance computing environment that can operate stably even if the supply chain expands. The technological excellence of these morph systems is advantageous not only at the manufacturing site, but also in the military and defense industry environment that requires large-scale material movement and strict traceability.

CEO Park Min-gyu, a graduate of Seoul National University’s Department of Aerospace Engineering, has published a number of international academic papers in the field of reinforcement learning, served as an AI researcher at the Korea Military Academy, and conducted defense and public AI projects. While working on a Palantir Foundry-based consulting project, he discovered the demand for data integration in the manufacturing and defense industries and decided to start a business. Co-founder Koo Ha-rim is a graduate of the Department of Mechanical Engineering at the National University of Singapore and has two startup experiences and is in charge of data integration and AI system implementation directly in the field.

Morph Systems expects 40% of its sales to come from U.S. customers since its first year, and to expand to more than 80% this year. Recently, in recognition of the excellence of data integration technology that can handle large-scale supply chains stably, it was selected for the TIPS program organized by the Ministry of SMEs and Startups and secured up to 500 million won in R&D funds. The selection of this tip was made on the recommendation of Mashup Ventures.

“After attracting this investment, we plan to implement a large-scale ontology-based computational and decision-making operation system centered on the U.S. market,” said Park Min-gyu, CEO of Morph Systems. “The ultimate goal is to expand to Neo-Cloud infrastructure and software layers optimized for specific industries and workloads based on our experience in operating field-oriented AI systems.”

Lee Seung-guk, a Mashup Ventures partner who led the investment, said, “The demand for data integration and decision-making automation is increasing rapidly in the process of re-industrialization and supply chain reorganization in the United States. Morph Systems is a team that solves core problems in the manufacturing and defense industry based on Palantir Foundry-based data integration technology and field-oriented experience, and it is expected to grow quickly in the U.S. market.”

Source link